Press
Releases
Press Releases
AVROBIO Announces Closing of Underwritten Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock.
Nov 24, 2020
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.
Nov 19, 2020
AVROBIO Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.
Nov 19, 2020
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite plasma lyso-Gb1 and plasma chitotriosidase as compared to baseline when the patient was on ERT Ongoing Fabry disease trials continue to demonstrate sustained durability, with first patient out
Nov 17, 2020
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Nov 06, 2020
AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
Expanded ex vivo lentiviral gene therapy pipeline with program for Hunter syndrome Received orphan drug designation from the European Commission for two lead programs, AVR-RD-01 for Fabry disease and AVR-RD-02 for Gaucher disease type 1 Clinical and pipeline updates to be shared at Virtual R&D Day
Nov 05, 2020
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 29, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the
Oct 29, 2020
AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day
Event to be webcast on Tuesday, Nov. 17, 2020 at 9:00 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a Virtual
Oct 26, 2020
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 21, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel , Ph.D., to its Board of Directors. Dr.
Oct 21, 2020
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2020-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to
Oct 06, 2020
Displaying 1 - 10 of 44